The raised guidance and strong royalty growth confirm the core business momentum, but the $5.1B debt overhang and declining net profit cap the upside. Watch for Rina-S and petosemtamab Phase 3 data readouts as key catalysts; the AbbVie trade secret litigation resuming in district court is a medium-term risk.
Drugs in focus
GMAB drug pipeline →rinatabart sesutecan
▲ Bullish Named in this 6-K- Impact
- Phase
- Phase 3
- Time to market
- Regulatory submission discussions are underway following positive Phase 3 data. If filed in 2026-2027, potential FDA approval could come in 2027-2028, though the timeline depends on regulatory interactions and whether accelerated pathways are pursued.
- Next catalyst
- None dated
What to watchThe Phase 3 RAINFOL-02 readout (Oct 23, 2026) was a major derisking event for Rina-S with highly compelling efficacy data. Watch the October 28 investor update for regulatory filing timelines and commercial opportunity sizing. The stock is near its 52-week high with strong technical momentum but RSI overbought at 78, near-term pullback risk exists after the recent run-up.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 6 $29.83entry
- T+1 · 3mo ago +4.76%α +4.15% · $31.25
- T+5 · 3mo ago +5.06%α +3.85% · $31.34
- T+20 · 3mo ago +15.35%α +14.75% · $34.41
- T+60 · 18d ago +91.28%α +92.95% · $57.06
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Genmab reported strong H1 2026 results with revenue up 25% YoY to $2,051M, driven by DARZALEX and Kesimpta royalties and EPKINLY sales. The company raised its full-year 2026 revenue guidance to $4.325-4.525B (from $4.065-4.395B) and adjusted operating profit guidance to $1.065-1.385B (from $0.900-1.400B). Positive Phase 3 data for epcoritamab in DLBCL and progress on Rina-S and petosemtamab support the pipeline, but net profit declined to $356M from $531M due to higher interest expense from the Merus acquisition debt and increased operating costs.
Key Facts
- Revenue increased 25% YoY to $2,051M for H1 2026.
- Full-year 2026 revenue guidance raised to $4.325-4.525B (midpoint $4.425B).
- Full-year 2026 adjusted operating profit guidance raised to $1.065-1.385B (midpoint $1.225B).
- DARZALEX royalties rose 20% to $1,306M; Kesimpta royalties rose 31% to $259M.
- EPKINLY/TEPKINLY global net sales grew 48% to $312M.
- Phase 3 EPCORE DLBCL-4 trial for epcoritamab met primary endpoint (improved PFS).
- Net profit declined to $356M from $531M due to $217M in interest/amortization expense on borrowings.
- Debt of $5.135B remains from the Merus acquisition; Term B Loan interest margin reduced from 3.00% to 2.00%.
Financial Impact
Revenue up 25% to $2,051M; net profit down 33% to $356M; guidance raised by ~$195M at midpoint for revenue and ~$75M for adjusted operating profit.
Risk Factors
- $5.1B debt from Merus acquisition creates interest expense drag on net profit.
- AbbVie trade secret litigation over Rina-S could resume in district court after ITC withdrawal.
- Chugai patent infringement complaint in Japan over EPKINLY poses potential sales disruption.
- High operating expense growth (28% adjusted) may pressure margins if revenue growth slows.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001434265-26-000108 |
| Document: 0001434265-26-000108-index-headers.html | 0001434265-26-000108 |
| Document: 0001434265-26-000108-index.html | 0001434265-26-000108 |
| Document: 0001434265-26-000108.txt | 0001434265-26-000108 |
Track record
31 reports on GMAB
2 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +44.33% at T+20 after the Oct 5, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $52.12 Now $51.57 −1.06% settles Dec 15
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $53.87 Now $51.57 −4.27% settles Dec 10
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $54.07 Now $51.57 −4.62% settles Dec 9
- Nov 5, 202611d ago 6-K Neutral 5/10 Entry $52.74 Now $51.57 −2.22% settles Dec 4
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $52.74 Now $51.57 −2.22% settles Dec 4
- Oct 28, 202619d ago 6-K Bullish 6/10 Entry $57.29 Now $51.57 −9.98% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers